44: Cure Cancer, Boost Global Growth

Episode Summary

Executive Summary: The episode centers on the economics of cancer, linking personal loss, public policy, medical innovation, and affordability. Bloomberg’s hosts interview Dr. Louis Weiner about progress since the U.S. declared a war on cancer, the promise of immunotherapy and the Cancer Moonshot, and the challenge of paying for increasingly effective but expensive treatments across unequal health systems.

Main Topics: Cancer as a global economic and human issue (Priority: 5/5): The hosts frame cancer not just as a medical problem but as a major driver of mortality, lost productivity, and family disruption worldwide. Progress in cancer treatment since 1971 (Priority: 5/5): Dr. Weiner explains that survival has improved substantially over decades due to research, better care, and new therapies, even as cancer incidence remains high. The Cancer Moonshot and public-private research investment (Priority: 4/5): The discussion covers the Obama/Biden Moonshot initiative and the need to reduce barriers and accelerate breakthroughs through coordinated funding and collaboration. Immunotherapy as a breakthrough frontier (Priority: 5/5): Weiner highlights checkpoint inhibitors and immune-based treatments as transformative advances that can produce major benefits, even cures, in some advanced cancers. Cost, coverage, and access to care (Priority: 5/5): A major theme is whether society can afford these therapies and how insurers and Medicare will determine who gets access, especially as treatments expand across many cancers. Global inequality in cancer care (Priority: 4/5): The conversation contrasts wealthy countries with poorer regions, arguing that access to screening and advanced therapies is far more limited outside developed economies.

Key Arguments: Cancer is both a public health crisis and an economic burden, with large losses from mortality, disability, and reduced productivity. Despite rising absolute case counts, U.S. cancer death rates have fallen steadily since 1990, indicating major progress in prevention and treatment. Many of the most promising advances, especially immunotherapy, depend on long-term research funding that was not guaranteed to pay off quickly. The Cancer Moonshot is meant to accelerate progress by cutting red tape and improving coordination among researchers, government, and industry. The biggest challenge ahead is not only scientific discovery but also access: expensive therapies must be matched to the patients most likely to benefit. Insurance companies generally cover approved, evidence-backed treatments, but they may resist experimental or intuition-based use. Global access to cancer care is worsening in relative terms because sophisticated therapies and even basic screening are concentrated in richer countries.

Data Points: U.S. annual cancer cases in 1971: roughly 1 million - Dr. Weiner compares the start of the war on cancer to the present. U.S. annual cancer cases now: roughly 1.6 million - Current annual incidence cited by Dr. Weiner. U.S. annual cancer deaths: about 585,000 - Estimated deaths in the U.S. this year. Historical cure rate in 1971: about 50% - Dr. Weiner says roughly half of patients were succumbing to cancer then. Current cure rate: roughly two out of three - Dr. Weiner says survival has improved substantially over 40 years. Annual decline in cancer death rate: every single year since 1990 - Used to illustrate sustained progress in the U.S. Worldwide economic impact of cancer: nearly $1 trillion - Premature death and disability from cancer worldwide. Share of global GDP lost: 1.5% - Alternative expression of the global economic toll of cancer. Global spending on cancer drugs in 2015: $107 billion - Cited as part of the pharma and biotech deep dive. Projected global spending on cancer drugs by 2020: $178 billion - Forecast for future worldwide cancer drug spending. U.S. cancer drug spending growth: up 72% in the last five years - Indicates rapid escalation in domestic treatment costs. Cancer mortality comparison: second leading cause of death in the U.S.; number one in some global measures - Establishes the scale of the problem. Checkpoint inhibitor response breadth: about 25 different cancers - Dr. Weiner describes the range of cancers where PD-1/PD-L1 drugs can work. Immediate mortality pace: more than 3,000 people in the U.S. will die of cancer in the next two days - Used to emphasize urgency and unacceptable death rates.

Pivotal Quotes: "the topic of our show today is the economics of cancer" — Daniel Moss: Introduces the episode’s central theme and framing. "the immune system can go ahead and treat the cancer" — Dr. Louis Weiner: Explains the logic of immunotherapy and checkpoint blockade. "the greatest challenges we have... is that in that latter circumstance, we had the technology... In the area of cancer research and care, we have some of the tools we need... but there's still additional knowledge that needs to be created" — Dr. Louis Weiner: Contrasts the Moonshot landing with the scientific uncertainty of cancer research.

Implications: Cancer care is becoming more effective but also more expensive and unequal. Future progress will depend on sustained research investment, better patient selection for therapies, and policies that expand access without overwhelming health systems.